Mary Heenan
About
In The Last Decade
Mary Heenan
11 papers receiving 445 citations
Peers
Comparison fields: 5 of 82
- Oncology 222
- Molecular Biology 212
- Pharmacology 79
- Organic Chemistry 59
- Pulmonary and Respiratory Medicine 42
Countries citing papers authored by Mary Heenan
This map shows the geographic impact of Mary Heenan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Heenan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Heenan more than expected).
Fields of papers citing papers by Mary Heenan
This network shows the impact of papers produced by Mary Heenan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Heenan. The network helps show where Mary Heenan may publish in the future.
Co-authorship network of co-authors of Mary Heenan
This figure shows the co-authorship network connecting the top 25 collaborators of Mary Heenan. A scholar is included among the top collaborators of Mary Heenan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Heenan. Mary Heenan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 32 | |
| 2 | Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. | 41 |
| 3 | 37 | |
| 4 | Construction and transfection of a ribozyme targeting human caspase-3. | 4 |
| 5 | Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. | 27 |
| 6 | 28 | |
| 7 | 34 | |
| 8 | 220 | |
| 9 | 28 | |
| 10 | 8 | |
| 11 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.